NASDAQ · Biotechnology · USD
Dermata Therapeutics, Inc. (DRMA) Stock Analysis
Dermata Therapeutics, Inc. (DRMA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
DRMA Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.85
- Previous Close
- $0.87
- Day's Range
- 0.78–0.89
- 52-Week Range
- 0.60–4.66
- Volume
- 214.93K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.66
Valuation
- Market Cap
- $3.96M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −4.39
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$7.56M
- Shares Outstanding
- 4.96M
- 1-Year Return
- −80.73%
Dividend and dates
- Avg Volume
- 3.43M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, DRMA closed at $0.80, −80.73% over 1 year.
Dermata Therapeutics, Inc. (DRMA) has a market capitalization of $3.96M.
In fiscal 2025, DRMA reported revenue of $0.00.
DRMA Stock Return by Calendar Year
Dermata Therapeutics, Inc. (DRMA) return since Aug 2021: what $10,000 became
- 1 year
- $10,000 $1,927
- −80.73%
- 5 years
- $10,000 $0.75
- −99.99%
- Since Aug 2021
- $10,000 $0.64
- −99.99%
If you had invested $10,000 in Dermata Therapeutics, Inc. (DRMA) at the close on August 13, 2021, the earliest close on record here, it would have been worth $0.64 at the close on October 21, 2026: −99.99% in total, −84.44% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −65.54% |
| 2025 | −82.81% |
| 2024 | −85.25% |
| 2023 | −90.68% |
| 2022 | −76.49% |
| 2021 (partial year) | −66.47% |
As of October 21, 2026.
DRMA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$7.56M | — |
| 2024 | $0.00 | −$12.29M | — |
| 2023 | $0.00 | −$7.79M | — |
| 2022 | $0.00 | −$9.61M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$7.77M | −$7.56M | — |
| 2024 | $0.00 | — | −$12.51M | −$12.29M | — |
| 2023 | $0.00 | — | −$8.04M | −$7.79M | — |
| 2022 | $0.00 | — | −$9.67M | −$9.61M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Why Is Dermata Therapeutics Stock Gaining Thursday?
BenzingaDermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
YahooDermata Therapeutics Announces Over 71% Of Patients Had Overall Skin Improvements At Day 29 In Its Cosmetic Clinical Trial Of Tome Foundational Treatment
BenzingaPapulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories
YahooDermata Therapeutics Stock Surges 27% Pre-Market: Why is it Moving?
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B